The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Retatrutide for Weight Loss

Retatrutide weight loss research: triple agonist mechanisms, Phase 2 efficacy data, and protocol guide.

Phase 2 Weight Loss Results

Phase 2 titration schedule, mechanism, and clinical trial weight loss data for the triple GLP-1/GIP/glucagon agonist

Phase 2 Titration Schedule

Source: Jastreboff AM et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM 2023. N=338 participants with obesity (BMI ≥30), 48-week treatment period.

Why Retatrutide Produces Greater Weight Loss

Phase 2 titration schedule, mechanism, and clinical trial weight loss data for the triple GLP-1/GIP/glucagon agonist